Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S143000
Reexamination Certificate
active
07074805
ABSTRACT:
The isoquinoline compounds of formula (I)are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The “R”, “Z” and “L” variables are defined in the disclosure and the “X” variables are defined as follows:X1is CR1;X2is selected from the group consisting of N and CR2;X3is selected from the group consisting of N and CR3;X4is CR4; andX5is selected from the group consisting of N and C.
REFERENCES:
patent: 3647819 (1972-03-01), Kirchner
patent: 3711610 (1973-01-01), Kirchner
patent: 3814711 (1974-06-01), Eloy et al.
patent: 4958026 (1990-09-01), Schoellkopf et al.
patent: 5362878 (1994-11-01), Chang et al.
patent: 5444038 (1995-08-01), James et al.
patent: 5656634 (1997-08-01), Chang et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6291476 (2001-09-01), Kordik et al.
patent: 6472414 (2002-10-01), Biller et al.
patent: 6511998 (2003-01-01), Kordik et al.
patent: 6555539 (2003-04-01), Reich et al.
patent: 0418071 (1991-03-01), None
patent: 0609960 (1994-08-01), None
patent: 1 403 255 (2004-03-01), None
patent: 1 344 579 (1963-10-01), None
patent: 2020280 (1979-11-01), None
patent: WO91/13874 (1991-09-01), None
patent: 97/26240 (1997-07-01), None
patent: 00/50387 (2000-08-01), None
patent: 02/08221 (2002-01-01), None
patent: WO03/14064 (2003-02-01), None
patent: 03/014064 (2003-02-01), None
patent: WO03/22809 (2003-03-01), None
patent: 03/22809 (2003-03-01), None
patent: WO03/80578 (2003-10-01), None
Berge, et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences66:1-19 (1977) (Jan., 1977).
Caterina, et al., “Impaired Nociception and pain sensation in mice lacking the capsaicin receptor,”Science288:306-313 (2000) (Apr. 14, 2000).
Caterina, et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway,”Nature389:816-824 (1997) (Oct. 23, 1997).
Caterina, et al., “The Vanilloid Receptor: A Molecular gateway to the pain pathway,”Annual Review of Neuroscience24:487-517 (2001).
Collier, et al., Br. J. Pharmacol. Chemother. 32:295-310 (1968).
Davis, et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,”Nature405:183-187 (2000) (May 11, 2000).
Fowler, “Intravesical treatment of overactive bladder,”Urology 55(Supp 5A):60-64 (2000) (May, 2000).
Hayes, et al., “Cloning and functional expression of a human orthologue of rat vanilloid receptor-1,” Pain 88:205-215 (2000).
Nolano, et al., “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation,”Pain81:135-145 (1999).
Poste , et al.,Methods in Cell Biology, Academic Press, New York, N.Y. vol. 14:33-71 (1976).
Adams et al., “Dialkylaminoalkyquinolines,” J. Chem. Soc. 3066-3071 (1957).
Cannon et al., “Synthesis of N-alkyl derivatives of 4-(2′-aminothyl)indole,” J. Heterocyclic Chemistry 19:1195-1199 (1982) (Sep.-Oct., 1982).
Craig et al., “Derivatives of aminoisoquinolines,” J. Am. Chem. Soc. 64:783-784 (1942) (Nov., 1942).
Fieser et al., “A comparison of heterocyclic systems with benzene. VI. Quinines of the quinoline and isoquinoline series,” J. Amer. Chem. Soc. 57:1840-1844 (1935) (Oct. , 1935).
Forbes et al., “N-(1-methyl-5-indolyl)-N′-(3-pyridyl)urea hydrochloride: the first selective 5-HT1Creceptor antagonist,” J. Med. Chem. 36:1104-1107 (1993).
Gall et al., “171. On a few derivatives of heterocyclic carbonic acids IV. Metal ions and biological action, 36threport,” Helv. Chim. Acta 38(171):1421-1423 (1955) with translation.
Honma et al., “Structure-based generation of a new class of potent Cdk4 inhibitors: Newde Novodesign strategy and library design,” J. Med. Chem. 44:4615-4627 (2001).
Kawasaki et al., “A new approach to 4-(2-aminoethyl)indoles via Claisenortho-amide rearrangement of 3-hydroxy-2-methoxyindolines,” J. Chem. Soc. Chem. Commun. 10:781-782 (1990).
Kumar et al. “Antiparasitic agents: Part XV—Synthesis of 2-substituted 1(3)H-imidazo[4,5-f]isoquinolines as anthelmintic agents,” Indian Journal of Chemistry 31B:177-182 (1992) (Mar., 1992).
Mooney et al., “Potential antitumor agens, 10. Synthesis and biochemical properties of 5-N-alkylamino-,N,N-dialkylamino-, and N-alkylacetamido-1-formylisoquinoline thiosemicarbazones,” Journal of Medicinal Chemistry 17(11):1145-1150 (1974).
Naruto et al., “Photo-induced Friedel-Crafts reactions. IV>Indoleacetic acids,” Chemical and Pharmaceutical Bulletin, Tokyo, JP 20(10):2163-2171 (1972).
Prijs et al. “9. On a few derivatives of heterocyclic carbonic acids I . . . Metal ions and biological action, 16threport,” Helv. Chim. Acta 37:90-94 (1954) with translation.
Sato et al., “Construction of optically pure tryptophans from serine derived aziridine-2-carboxylates,” Tetrahedron Letters 30(31):4073-4076 (1989).
Taurins et al., “Thiazoloisoquinolines. IV. The synthesis and spectra of thiazolo[4,5-h]-and thiazolo[5,4-f]isoquinolines. The ultraviolet and proton magnetic resonance spectra of some substituted isoquinolines,” Canadian Journal of Chemistry 49(24):4054-4061 (1971).
Warpehoski et al., “Stereoelectronic factors influencing the biological activity and DNA intereaction of synthetic antitumor agents modeled on CC-1065,” J. Med. Chem. 31:590-603 (1988) (Issue No. 3).
Lichtenthaler et al., “Nucleosides. 44. Benzo-separated Pyrazolopyrimidines: Expeditions Synthesis of [3,4-g] and [3,4-h]-linked Pyrazoloquinazolinones” Tetrahedron Letters 22(44) :4397-4400 (1981).
Nunn et al., “Semmler-Wolf Aromatization and Abnormal Beckmann and Schmidt Reactions of 3-Alkyl-4Oxo-1-phenyl-4,5,6,7,-tetrahydroindazoles and their oximes in polyphosphoric acid” J. Chem. Soc. Perkin Transactions 1, 1973 No. 22:2697-2703 (1973).
R. Gall: Über Einige Derivative Heterocyclischer Carbonsaüren, Helv. Chim. Acta, vol. 37 (1954), pp. 90-94 (English translation summary-last page).
Bayburt Erol K.
DiDomenico, Jr. Stanley
Drizin Irene
Gomtsyan Arthur R.
Koenig John R.
Abbott Laboratories
Crane L. E.
Gabryleda Ferari-Dileo
LandOfFree
Fused azabicyclic compounds that inhibit vanilloid receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused azabicyclic compounds that inhibit vanilloid receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused azabicyclic compounds that inhibit vanilloid receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525147